EP3541366
JAFNAÐAR SAMSETNINGAR EXENDÍNS (9 39)
:
EP einkaleyfi í gildi á Íslandi:
21.11.2017:
25.12.2024:
17871296.4
:
3.3.2025:
15.4.2025
:
20.11.2037:
20.11.2025
:
BUFFERED FORMULATIONS OF EXENDIN (9-39)
21.11.2017
25.12.2024
3.3.2025
15.4.2025
20.11.2025
:
Amylyx Pharmaceuticals, Inc.:
43 Thorndike St., Cambridge, MA 02141, US
:
The Board of Trustees of the Leland Stanford Junior University:
Office of the General Counsel Building 170, Third Floor, Main Quad P.O. Box 20386, Stanford, CA 94305-2038, US
:
XIONG, Xiaofeng:
Palo Alto, California 94306, US
:
ODINK, Debra:
Palo Alto, California 94306, US
:
CRAIG, Colleen M.:
Palo Alto, California 94306, US
:
SMITH, Christine M.N.:
Palo Alto, California 94306, US
:
MCLAUGHLIN, Tracey L.:
Stanford, California 94305, US
:
COSMOVICI INTELLECTUAL PROPERTY SARL:
11 Boulevard Sébastopol, FR
:
201662424979 P:
21.11.2016:
US
:
201762517065 P:
8.6.2017:
US
:
US2017062838:
21.11.2017
:
A61K 9/00, A61K 9/08, A61K 47/12, A61K 47/26, A61K 38/16, A61K 38/26, A61P 3/10